Once-monthly oral ibandronate is at least as effective as daily oral ibandronate in postmenopausal osteoporosis: 2-year findings from MOBILE.

被引：0
|
作者：
McClung, MR
Drezner, MK
Reginster, JY
Bolognese, M
Hughes, C
Mairon, N
Bonvoisin, B
Delmas, PD
机构：
[1] Oregon Osteoporosis Ctr, Portland, OR USA
[2] Univ Wisconsin, Madison, WI 53706 USA
[3] Univ Liege, B-4000 Liege, Belgium
[4] Bethesda Hlth Res, Bethesda, MD USA
[5] F Hoffmann La Roche Ltd, Basel, Switzerland
[6] Univ Lyon 1, F-69365 Lyon, France
[7] INSERM, Res Unit 403, F-69008 Lyon, France
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2005年 / 20卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S395 / S395
页数：1
相关论文
共 50 条
  • [21] Upper gastrointestinal safety and tolerability profile of once-monthly and daily oral ibandronate: Mobile 2-year analysis
    Czerwinski, E.
    Nuti, R.
    Greenwald, M.
    Burdeska, A.
    Leigh, C.
    Reginster, J. Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 415 - 415
  • [22] Favorable safety profile of once-monthly oral ibandronate in postmenopausal osteoporosis: 1-year results from mobile
    Nuti, R
    Stakkestad, JA
    Czerwinski, E
    Leigh, C
    Mairon, N
    Bonvoisin, B
    Cooper, C
    BONE, 2005, 36 : S418 - S419
  • [23] Once-monthly oral ibandronate effectively normalizes biochemical markers of bone resorption in postmenopausal osteoporosis: MOBILE 2-year analysis.
    Miller, PD
    Kendler, DL
    Garnero, P
    Silverman, S
    Hughes, C
    Mairon, N
    Bonvoisin, B
    Christiansen, C
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S284 - S284
  • [24] EFFICACY OF ONCE-MONTHLY ORAL BISPHOSPHONATES (IBANDRONATE AND RISEDRONATE) IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS
    Epstein, S.
    McCloskey, E.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 146 - 146
  • [25] Monthly oral ibandronate is well tolerated in women with postmenopausal osteoporosis: 1-year results from MOBILE.
    Lewiecki, EM
    Miller, PD
    Lorenc, R
    Hughes, C
    Bonvoisin, B
    McClung, MR
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 : S446 - S446
  • [26] Upper gastrointestinal safety and tolerability profile of once-monthly oral ibandronate: Mobile 2-year analysis
    不详
    CALCIFIED TISSUE INTERNATIONAL, 2006, 78 : S134 - S134
  • [27] Once-monthly oral ibandronate versus weekly oral alendronate in postmenopausal osteoporosis: Rationale and design of motion
    Epstein, S.
    Borges, J. L. C.
    Mautalen, C.
    Gonzalez Macias, J.
    Mahoney, P.
    El Azzouzi, B.
    Masanauskaite, D.
    Cosman, F.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S252 - S252
  • [28] Upper gastrointestinal safety and tolerability profile of once-monthly and daily oral ibandronate is similar in postmenopausal osteoporosis:: 1-year results from mobile
    Adami, S
    Tankó, LB
    Nuti, R
    Leigh, C
    Mairon, N
    Sedarati, F
    Reginster, JY
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 364 - 364
  • [29] Efficacy and tolerability of once-monthly Ibandronate in postmenopausal osteoporosis
    Dasic, Gorana
    Lewiecki, E. Michael
    Miller, Paul D.
    Sunyecz, John
    Emkey, Ron
    OBSTETRICS AND GYNECOLOGY, 2006, 107 (04): : 91S - 92S
  • [30] Monthly oral ibandronate significantly reduces bone resorption in postmenopausal osteoporosis: 1-year results from MOBILE.
    Recker, RR
    Kendler, DL
    Adami, S
    Hughes, C
    Dumont, E
    Schimmer, RC
    Cooper, C
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 : S94 - S94
12345